Literature DB >> 15917118

Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures.

Stefan Oscarson1, Mia Alpe, Pär Svahnberg, Antonio Nakouzi, Arturo Casadevall.   

Abstract

Antibodies to the glucuronoxylomannan (GXM) component of the polysaccharide capsule of Cryptococcus neoformans are protective and GXM-protein conjugate vaccines can elicit protective immune responses. We report the synthesis of a heptasaccharide oligosaccharide representing the putative dominant motif of serotype A GXM and demonstrate that it is recognized by some monoclonal antibodies (mAbs) generated to GXM. Conjugation of the heptasaccharide to human serum albumin (HSA) resulted in an immunogenic compound that elicited high-titer IgG responses in mice when given with complete Freund's adjuvant. The antibody response elicited by the oligosaccharide conjugate vaccine had characteristics of a T-cell-dependent response. The availability of an immunogenic oligosaccharide representing a structural motif of GXM will prove useful in studies of antibody epitope specificity and represents a potential synthetic oligosaccharide vaccine against this fungal pathogen.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15917118     DOI: 10.1016/j.vaccine.2005.02.029

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport.

Authors:  Marcio L Rodrigues; Leonardo Nimrichter; Débora L Oliveira; Susana Frases; Kildare Miranda; Oscar Zaragoza; Mauricio Alvarez; Antonio Nakouzi; Marta Feldmesser; Arturo Casadevall
Journal:  Eukaryot Cell       Date:  2006-11-17

Review 2.  Biosynthesis and immunogenicity of glucosylceramide in Cryptococcus neoformans and other human pathogens.

Authors:  Ryan Rhome; Travis McQuiston; Talar Kechichian; Alicja Bielawska; Mirko Hennig; Monica Drago; Giulia Morace; Chiara Luberto; Maurizio Del Poeta
Journal:  Eukaryot Cell       Date:  2007-08-10

Review 3.  Carbohydrate vaccines: developing sweet solutions to sticky situations?

Authors:  Rena D Astronomo; Dennis R Burton
Journal:  Nat Rev Drug Discov       Date:  2010-04       Impact factor: 84.694

4.  A Monoclonal Antibody to Cryptococcus neoformans Glucuronoxylomannan Manifests Hydrolytic Activity for Both Peptides and Polysaccharides.

Authors:  Anthony Bowen; Maggie P Wear; Radames J B Cordero; Stefan Oscarson; Arturo Casadevall
Journal:  J Biol Chem       Date:  2016-11-21       Impact factor: 5.157

5.  A glycan FRET assay for detection and characterization of catalytic antibodies to the Cryptococcus neoformans capsule.

Authors:  Conor J Crawford; Maggie P Wear; Daniel F Q Smith; Clotilde d'Errico; Scott A McConnell; Arturo Casadevall; Stefan Oscarson
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-02       Impact factor: 11.205

6.  Binding of glucuronoxylomannan to the CD14 receptor in human A549 alveolar cells induces interleukin-8 production.

Authors:  Fabiane M Barbosa; Fernanda L Fonseca; Rodrigo T Figueiredo; Marcelo T Bozza; Arturo Casadevall; Leonardo Nimrichter; Marcio L Rodrigues
Journal:  Clin Vaccine Immunol       Date:  2006-11-08

Review 7.  The capsule of the fungal pathogen Cryptococcus neoformans.

Authors:  Oscar Zaragoza; Marcio L Rodrigues; Magdia De Jesus; Susana Frases; Ekaterina Dadachova; Arturo Casadevall
Journal:  Adv Appl Microbiol       Date:  2009       Impact factor: 5.086

8.  The elastic properties of the Cryptococcus neoformans capsule.

Authors:  Susana Frases; Bruno Pontes; Leonardo Nimrichter; Marcio L Rodrigues; Nathan B Viana; Arturo Casadevall
Journal:  Biophys J       Date:  2009-08-19       Impact factor: 4.033

Review 9.  Attempts at a peptide vaccine against paracoccidioidomycosis, adjuvant to chemotherapy.

Authors:  Luiz R Travassos; Elaine G Rodrigues; Leo K Iwai; Carlos P Taborda
Journal:  Mycopathologia       Date:  2008 Apr-May       Impact factor: 2.574

10.  The common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies.

Authors:  Antonio Nakouzi; Tong Zhang; Stefan Oscarson; Arturo Casadevall
Journal:  Vaccine       Date:  2009-04-19       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.